Brinton Pharmaceutical gets DGCI nod for Faviton, Favipiravir tablets

▴ Brinton Pharmaceutical gets DGCI nod for Faviton, Favipiravir tablets
Pune based Brinton Pharmaceutical gets DGCI nod for Favipiravir

Brinton Pharmaceuticals on Thursday said it has received approval from the Drugs Controller General of India (DCGI) to market antiviral drug Favipiravir under the brand name 'Faviton' for the treatment of COVID-19 patients.

To be available in 200 mg tablets, the drug will be sold at a maximum retail price of Rs 59 per tablet, Brinton Pharmaceuticals said in a statement. Emerging favorable global clinical evidence suggests, Favipiravir is an effective treatment option in the management of mild-to-moderate COVID-19, it added.

In India, Favipiravir was first approved by the regulatory authorities in June 2020 under emergency use authorisation to treat COVID-19 patients, Brinton Pharmaceuticals said.

"Our strategic intent will be to improve the access through our strong distribution network that will help make Faviton available across all COVID treatment centres and our MRP is Rs 59 per tablet," Brinton Pharma CMD Rahul Kumar Darda said.

The company will be marketing this drug in India and will also export it, the statement said.

Faviton is a generic version of Avigan of Fujifilm Toyama Chemical Co Ltd, a subsidiary of Fujifilm Corporation.

An off-patent anti-viral drug Favipiravir, originally discovered by Fuji, Japan has shown promise in clinical trials for the treatment of Covid-19 patients, especially the mild and the moderate patients.

Meanwhile, CSIR constituent lab CSIR-Indian Institute of Chemical Technology (CSIR-IICT) has developed a cost-effective process using locally available chemicals to synthesize this Active Pharmaceutical Ingredient (API) and transferred the technology to leading pharmaceutical industry M/s Cipla Limited.

Cipla has scaled up the process in their manufacturing facility and approached DCGI for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help patients suffering from Covid-19.

Commenting on the development, Director CSIR-IICR, Dr. S Chandrashekhar said that the technology provided by CSIR-IICT is very efficient and makes it affordable and allows Cipla to make large quantities of the product within a short span of time.

DG-CSIR, Dr. Shekhar C Mande observed that CSIR is working with industry in developing quick solutions and products for mitigation of Covid-19 and this partnership with Cipla is an example of how CSIR is committed in bringing repurposed drugs on a fast track.

Tags : #BrintonPharmaceuticals #Cipla #Favipiravir #CheapFavipiravir #Avigan #FujiFilm #DGCI #CoronaCure #CovidNewsUpdate #LatestCovidNews #CSIR

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026